{"id":"https://openalex.org/W2004188571","doi":"https://doi.org/10.1159/000218377","title":"Miltefosine Solution: Prognostic Factors for the Outcome of Topical Treatment of Skin Meta-static Breast Cancer","display_name":"Miltefosine Solution: Prognostic Factors for the Outcome of Topical Treatment of Skin Meta-static Breast Cancer","publication_year":2009,"publication_date":"2009-05-08","ids":{"openalex":"https://openalex.org/W2004188571","doi":"https://doi.org/10.1159/000218377","mag":"2004188571"},"language":"en","primary_location":{"id":"doi:10.1159/000218377","doi":"https://doi.org/10.1159/000218377","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000218377","pdf_url":null,"source":{"id":"https://openalex.org/S4210228507","display_name":"Onkologie","issn_l":"0378-584X","issn":["0378-584X","1423-0240"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Onkologie","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050473616","display_name":"HERBERT SINDERMANN","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Sindermann","raw_affiliation_strings":["Abteilung Klinische Tumorforschung,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abteilung Klinische Tumorforschung,","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"K. Junge","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Junge","raw_affiliation_strings":["Abteilung Biometrie, ASTA Medica AG, Frankfurt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abteilung Biometrie, ASTA Medica AG, Frankfurt","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113331833","display_name":"K. Burk","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Burk","raw_affiliation_strings":["Abteilung Klinische Tumorforschung,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abteilung Klinische Tumorforschung,","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":null,"issue":null,"first_page":"21","last_page":"26"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.6880000233650208,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.6880000233650208,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.1378999948501587,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12992","display_name":"Metastasis and carcinoma case studies","score":0.04729999974370003,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/miltefosine","display_name":"miltefosine","score":0.984000027179718},{"id":"https://openalex.org/keywords/cutaneous-metastasis","display_name":"cutaneous metastasis","score":0.8190000057220459},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.9879999756813049},{"id":"https://openalex.org/keywords/topical-chemotherapy","display_name":"topical chemotherapy","score":0.765999972820282},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.9599999785423279},{"id":"https://openalex.org/keywords/depth-of-infiltration","display_name":"depth of infiltration","score":0.9369999766349792},{"id":"https://openalex.org/keywords/nodular-lesions","display_name":"nodular lesions","score":0.628000020980835},{"id":"https://openalex.org/keywords/endocrine-therapy","display_name":"endocrine therapy","score":0.6859999895095825},{"id":"https://openalex.org/keywords/pruritus","display_name":"pruritus","score":0.777999997138977},{"id":"https://openalex.org/keywords/treatment-tolerability","display_name":"treatment tolerability","score":0.765999972820282},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.9229999780654907}],"concepts":[{"id":"https://openalex.org/C2781417161","wikidata":"https://www.wikidata.org/wiki/Q411787","display_name":"Miltefosine","level":4,"score":0.8669713139533997},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7555561065673828},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7049416899681091},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.5163685083389282},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46840402483940125},{"id":"https://openalex.org/C2779121184","wikidata":"https://www.wikidata.org/wiki/Q1166142","display_name":"Erythema","level":2,"score":0.4532984793186188},{"id":"https://openalex.org/C2777789703","wikidata":"https://www.wikidata.org/wiki/Q192102","display_name":"Skin cancer","level":3,"score":0.4311736524105072},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43005362153053284},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.42208585143089294},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.4219023287296295},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.26704347133636475},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2269621193408966},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.17834952473640442},{"id":"https://openalex.org/C2776555147","wikidata":"https://www.wikidata.org/wiki/Q331283","display_name":"Leishmaniasis","level":2,"score":0.1772584617137909},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.15558511018753052},{"id":"https://openalex.org/C2778689377","wikidata":"https://www.wikidata.org/wiki/Q2046113","display_name":"Visceral leishmaniasis","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1159/000218377","doi":"https://doi.org/10.1159/000218377","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000218377","pdf_url":null,"source":{"id":"https://openalex.org/S4210228507","display_name":"Onkologie","issn_l":"0378-584X","issn":["0378-584X","1423-0240"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Onkologie","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2032352006","https://openalex.org/W2007959663","https://openalex.org/W1960406178","https://openalex.org/W4300530401","https://openalex.org/W2074534566","https://openalex.org/W2074777382","https://openalex.org/W9160517","https://openalex.org/W1999995909","https://openalex.org/W2032556493","https://openalex.org/W2046776026"],"abstract_inverted_index":{"Background:":[0],"Miltefosine":[1,248],"solution":[2,47,154,249],"has":[3,26],"been":[4,27,53],"used":[5],"for":[6,33,70,100,229,244,283,292],"the":[7,95,144,169,178,193,226],"topical":[8],"treatment":[9,236,256,281],"of":[10,19,64,72,90,102,123,146,159,175,186,214,235,267],"skin":[11,103,170,187,198],"metastases":[12],"from":[13,21,41],"breast":[14],"cancer.":[15],"An":[16],"overview":[17,57],"analysis":[18,274],"data":[20,65,290],"clinical":[22],"phase":[23,49],"II":[24,50],"trials":[25,51],"performed":[28],"to":[29,76,126,167,177,184],"identify":[30],"prognostic":[31,98],"factors":[32,69,270],"efficacy":[34],"and":[35,38,74,83,111,205,207,253],"tolerability.":[36],"Materials":[37],"Methods:":[39],"Results":[40],"287":[42],"patients":[43,117,138,260],"treated":[44],"with":[45,139,232,261,264],"miltefosine":[46,153],"in":[48,55,116,225,259,280],"have":[52],"included":[54],"an":[56,61,251,278],"analysis.":[58],"This":[59],"involved":[60],"extramural":[62],"review":[63],"on":[66,157],"efficacy.":[67],"Prognostic":[68,269],"quality":[71],"response":[73,101,107,173],"time":[75,183],"progression":[77,185],"were":[78,220],"analyzed":[79],"by":[80,202,272],"a":[81,84,160,172,245,289],"logit":[82],"Weibull":[85],"model,":[86],"respectively.":[87],"Results:":[88],"Depth":[89],"infiltration":[91,131],"was":[92,114,149,155,180,192],"identified":[93,271],"as":[94,277,288],"most":[96,194],"relevant":[97],"factor":[99],"lesions.":[104],"A":[105,223],"39%":[106],"rate":[108,145,174,228],"(complete,":[109],"partial":[110],"minor":[112],"responses)":[113],"achieved":[115],"having":[118],"small":[119],"nodular":[120],"lesions":[121,140,188,263],"(diameter":[122],"nodules":[124],"up":[125],"1":[127],"cm)":[128],"and/or":[129],"lymphangitic":[130],"without":[132],"deep":[133],"subcutaneous":[134],"tumor":[135],"mass.":[136],"In":[137,151,211],"outside":[141],"these":[142],"limits,":[143],"objective":[147],"regressions":[148],"13%.":[150],"case":[152],"added":[156],"top":[158],"systemic":[161,215],"endocrine":[162],"therapy":[163],"which":[164],"had":[165],"failed":[166],"control":[168],"lesions,":[171],"38%":[176],"combination":[179],"observed":[181],"(median":[182],"27":[189],"weeks).":[190],"Pruritus":[191],"frequently":[195],"reported":[196],"local":[197,218,230],"reaction":[199],"(31%),":[200],"followed":[201],"erythema":[203],"(18%),":[204],"pain":[206],"burning":[208],"(10%":[209],"each).":[210],"virtual":[212],"absence":[213],"side":[216],"effects,":[217],"reactions":[219,231],"generally":[221],"tolerable.":[222],"decrease":[224],"hazard":[227],"increasing":[233],"duration":[234],"indicates":[237],"that":[238],"there":[239],"is":[240,250],"no":[241],"significant":[242],"risk":[243],"sensitization.":[246],"Conclusions:":[247],"effective":[252],"tolerable":[254],"new":[255],"modality,":[257],"especially":[258],"cutaneous":[262],"limited":[265],"depth":[266],"infiltration.":[268],"this":[273],"may":[275],"serve":[276],"aid":[279],"planning":[282],"individual":[284],"patients,":[285],"but":[286],"also":[287],"base":[291],"future,":[293],"confirmatory":[294],"trials.":[295]},"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}